Get all your news in one place.
100's of premium titles.
One app.
Start reading
Los Angeles Times
Los Angeles Times
Business
Michael Hiltzik

Michael Hiltzik: Eli Lilly is slashing insulin prices, but hold your applause

Eli Lilly & Co. played the altruism card like a champ on Mar. 1, when it announced steep price cuts on its insulin products of as much as 70%.

The big drug company said its action was all about helping diabetes patients, its goal being to "help Americans who may have difficulty navigating a complex healthcare system that may keep them from getting affordable insulin."

According to Lilly Chairman and Chief Executive David Ricks, America's healthcare system "still does not provide affordable insulin for everyone, and that needs to change."

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.